


Noah Worcester
Dermatological Society

64TH ANNUAL MEETING

N A P A , C A
MAY 3-7, 2023

MEETING
PROGRAM

WWW.NOAHDERM.ORG



Noah Worchester Dermatological Society

SIXTY-FOURTH ANNUAL MEETING

May 3 - 7, 2023

Westin Verasa Napa

Napa, California

www.noahderm.org

Welcome to Noah 64!

Welcome to Napa and the **Best Noah Worcester Dermatological Society Meeting ever!** It has been an absolute honor to assemble this program, which will highlight practice pearls and new research, technologies and treatment options for alopecia, dermatitis, psoriasis, autoimmune skin diseases, actinic keratoses, melanoma and non-melanoma skin cancer. To maximize CME credits for the meeting (13.50 CME hours!), we have also added a “Pinot and Pearls” session and an “Aesthetics Panel” Thursday, May 4 from 4-6 PM for rapid fire case reports, and engaging interactive and collegial conversations with a side of Napa wine.

We have outstanding guests from the East Coast and Kansas City, home of the Super Bowl Champions!, for the Weiner and Perry lectures. Finally, the meeting is organized by themes and panels, and we have some new speakers on surgical and medical topics.

There are non-CME breakfast and lunch sessions to keep us inclusive and interactive. Please make every effort to attend all of these sessions and take a moment to thank our industry partners for their support and attendance, share your thoughts on the lectures with them, and interact with them at our social events. Most importantly, help them remember why we are grateful for our industry relationships.

We want to thank the presenters for their dedication to our education and to Nicole Brandt and Kortney Incorvaia for their tireless efforts to make the meeting possible. It is our privilege to have assembled the scientific program for the 2023 Noah meeting, and in addition to making this the “Best Noah Ever”, we want this to be the best meeting that you will attend all year.

We’re so excited you are here!

Warmest Regards,

Alina Grzybowski Bridges, DO
Natasha Atanaskova Mesinkovska, MD
2023 Scientific Committee Co-Chairs

A Brief History of the Noah Worcester Dermatological Society

In 1957 the concept of a dermatological society composed of former residents, fellows, and faculty members of the Department of Dermatology of the University of Cincinnati College of Medicine was proposed. An organization committee was formed consisting of Drs. Donald Birmingham, Mitchell Ede, Leon Goldman, Edwin Higgins, Daniel J. Kindel, H. Jerry Lavender, Harry Nieman, Robert Preston, John B. Squires, Raymond Suskind, and Alfred L. Weiner, Chairman.

It was soon apparent that there was considerable interest in the Society among Cincinnati colleagues. As a result, it was determined that the Society's best interests would be served if it were to become the nucleus of a modest national organization. The founding meeting of the Society was held at the Eden Roc Hotel, Miami Beach, Florida, April 23-27, 1958. The constitution, authored by the committee of Drs. Mitchell Ede, Leon Goldman, and H. Jerry Lavender, Chairman, was ratified and a charter board of trustees was elected. The charter trustees were Drs. Donald Cole, Mitchell Ede, Edwin Higgins, Daniel J. Kindel, H. Jerry Lavender, Raymond Suskind, and Alfred L. Weiner. The trustees elected as charter officers included Dr. Weiner, President; Dr. Kindel, Vice President; and Dr. Lavender, Secretary.

There were 38 attendees at the first meeting and a most satisfactory scientific program was presented. A well-planned round of social activities led to pleasant diversion, and a sense of genuine camaraderie among those attending was immediately evident.

The Noah Worcester Dermatological Society was selected as the name for the new organization to memorialize the often unrecognized author of the first American textbook of dermatology, Dr. Noah Worcester. A graduate of Dartmouth Medical School, Dr. Worcester came to Cincinnati to associate with Dr. R.D. Mussey the Chair of Surgery in the Medical College of Ohio in Cincinnati in 1838. Eventually, his successful medical practice made it possible for Worcester to acquire further knowledge by studying in Europe. In 1841, he journeyed abroad to study the methods of Laennec in physical diagnosis and further his interest in pathology. During his stay in Paris, Worcester devoted a considerable amount of time to St. Louis Hospital, at that time the world's foremost center of dermatologic teaching and research. Although Worcester's interest in diseases of the skin was a secondary one, it was nevertheless genuine and intense. He returned to America and to Cincinnati in 1842 to resume practice with Dr. Mussey and later to become a professor of physical diagnosis and pathology at the Medical College of Ohio. He also treated dermatologic patients, applying his newly acquired knowledge, and lectured on diseases of the skin – likely the first American to do so. In 1843, Worcester accepted a professorship in general pathology, physical diagnosis, and diseases of the skin

in the Medical Department of the Western Reserve College in Cleveland, Ohio. In addition to teaching and attending private patients in the Cleveland area, Worcester also traveled to Cincinnati from time to time to attend to patients. During this period, despite failing health, Worcester wrote his textbook of dermatology, "A Synopsis of the Symptomatic Diagnosis and Treatment of the More Common and Important Diseases of the Skin," printed in Cincinnati in 1845.

Dr. Worcester died of tuberculosis at the age of 34 shortly after his textbook was written. He is buried in Spring Grove Cemetery in Cincinnati. It seems appropriate that a dermatological society originating at the University of Cincinnati bear Dr. Worcester's name and that the significance of his authorship of the first American textbook of dermatology is recognized.

Following the meeting in 1958, subsequent meetings of the "Noah Derm Society" have been held annually in late winter or early spring. There have also been annual reunions during the course of the American Academy of Dermatology meetings.

The Noah Worcester Dermatological Society has continued to accomplish its objective to provide and nurture a small national organization characterized by high-caliber scientific dermatologic programs and familial association among its members. It is the general feeling of the Board of Trustees and of the members of the Society that the membership roster is selectively limited in order to assure the continuation of this intimacy and the academic standards of the scientific programs.

Alfred L. Weiner, MD
Founder

PRESIDENTS

*Alfred L. Weiner, MD 1958-1959 (Founder)
*Daniel J. Kindel, MD 1959-1960
*H. Jerry Lavender, MD 1960-1961
*Ashton L. Welsh, MD 1961-1962
*Duncan O. Poth, MD 1962-1963
*Lawrence C. Goldberg, MD 1963-1964
*Robert Pittelkow, MD 1964-1965
*Leonard S. Markson, MD 1965-1966
*Coleman Mopper, MD 1966-1967
*Harold O. Perry, MD 1967-1968
*Jack L. Derzavis, MD 1968-1969
*Michael J. Mitchell, MD 1969-1970
*Hyman J. Burstein, MD 1970-1971
Sigfrid Muller, MD 1971-1972
*Daniel F. Richfield, MD 1972-1973
*Arthur B. Kern, MD 1973-1974
*Richard Q. Crotty, MD 1974-1975
*Mauray J. Tye, MD 1975-1976
*Isadore Fisher, MD 1976-1977
*Harold Plotnick, MD 1977-1978
Henry Roenigk, Jr., MD 1978-1979
Z. Charles Fixler, MD 1979-1980
Robert M. Fine, MD 1980-1981
*Morris M. Meister, MD 1981-1982
Jerral S. Seibert, MD 1982-1983
*Darl Vanderploeg, MD 1983-1984
*Herbert B. Christianson, MD 1984-1985
*Richard J. Ferrara, MD 1985-1986
*Stuart M. Brown, MD 1986-1987
*James W. Bard, MD 1987-1988
Frank E. Dunlap, MD 1988-1989
*Hiram M. Sturm, MD 1989-1990

James A. Zalla, MD 1990-1991
*Arnold L. Schroeter, MD 1991-1992
*K. William Kitzmiller, MD 1992-1993
*J. B. Pinski, MD 1993-1994
*William F. Schorr, MD 1994-1995
*Harold L. Saferstein, MD 1995-1996
*Harry L. Roth, MD 1996-1997
Raymond M. Handler, MD 1997-1998
Sorrel S. Resnik, MD 1998-1999
Margaret Waisman, MD 1999-2000
Alan E. Lasser, MD 2000-2001
Stephen P. Stone, MD 2001-2002
John W. White, Jr, MD 2002-2003
Michael J. Scott III, DO 2003-2004
Ivor Caro, MD 2004-2005
Kevin S. Pinski, MD 2005-2006
*Robert Katz, MD 2006-2007
*J. Robert West, MD 2007-2008
*Darryl M. Bronson, MD 2008-2009
Marianne O'Donoghue, MD 2009-2010
Neil Fenske, MD 2010-2011
Elaine Young, MD 2011-2012
Suzanne Connolly, MD 2012-2013
Anthony Fransway, MD 2013-2014
James O. Ertle, MD 2014-2015
Jennifer L. Vesper, MD 2015-2016
Clay Cockerell, MD 2016 - 2017
*James Nordlund, MD 2017 - 2018
Peter Muelleman, MD 2018 - 2019
Daniel Siegel, MD 2019 - 2021
Neil Sadick, MD 2021 - 2022
Evan Schlam, MD 2022 - 2023

*Deceased

SECRETARY-TREASURERS

* H. Jerry Lavender, MD 1958-1959
* Edwin Higgins, MD 1959-1960
* Daniel F. Richfield, MD 1960-1971
* Harold Plotnick, MD 1971-1976
Jerral S. Siebert, MD 1976-1981
* James W. Bard, MD 1981-1986
* K. William Kitzmiller, MD 1986-1991
Raymond M. Handler, MD 1991-1996
Alan E. Lasser, MD 1996-2000
Ivor Caro, MD 2000-2004
* Darryl M. Bronson, MD 2004-2008
Michael Greenberg, MD 2008-2012
Clay J. Cockerell, MD 2012-2016
Neil Sadick, MD 2016-2018
Neal Bhatia, MD 2018 - 2024

BOARD OF TRUSTEES

Evan Schlam, MD, *President*
Michael Greenberg, MD, *President-Elect*
Neal Bhatia, MD, *Secretary-Treasurer*
Neil Sadick, MD, *Past-President*
Antonella Calame, MD
David Shupp, MD
Mark Zalla, MD
Brian Adams, MD
Craig Eichler, MD
Lisa Garner, MD
Alison Ehrlich, MD
Andrew Ondo, MD
Cyndi Yag-Howard, MD
Anisha Patel, *Young Observer*

STAFF

Nicole Brandt, *Executive Director*
Kortney Incorvaia, *Meeting Manager*

COMMITTEES

GENERAL ARRANGEMENTS

Antoanella Calame

SCIENTIFIC

Alina Bridges

Natasha Mesinkovska

FINANCE

Michael O'Donoghue, Chair

Anisha Patel

ENDOWMENT

Peter Muelleman, Chair

Murad Alam

Michael O'Donoghue

CONSTITUTION

Margaret Waisman, Chair

Christen Mowad

MEMBERSHIP

Lawrence Stokar, Chair

Carrie Davis

Michael Greenberg

David Shupp

BENEFACTOR

Lawrence Green, Chair

Seemal Desai

Brad Glick

Michael Heffernan

George Lewitt

NEW MEMBER ORIENTATION

Carla Bauman

Melissa Piliang

Jennifer Vesper

David Wetter

RESIDENT LECTURESHIP

Michael O'Donoghue, Chair

Carrie Davis

Peter Friedman

David Wetter

ARCHIVES

Z. Charles Fixler

Louis Kuchnir

NOMINATING

Neal Bhatia

Michael Greenberg

Julie Hodge

Evan Schlam

LEGAL AND ETHICS

James Ertle, Chair

Michael O'Donoghue

Jennifer Vesper

CONTRACTS

James Ulery, Jr.

James Zalla

BLANCHED SOLDIERS OF NOAH

Carla Bauman

SPORTS

Morgan Magid

Brian Adams

NEW MEMBERS 2022 - 2023

Laura Ferris, MD, PhD
Pittsburgh, PA

Alexandra Flamm, MD
Hershey, PA

Robert Glinert, MD
Madison, WI

Shadi Kourosh, MD
Boston, MA

Keith Lopatka, MD
Palos Heights, IL

Alexander Meves, MD, MBA
Rochester, MN

Heidi Prather, MD
Austin, TX

Michelle Tarbox, MD
Lubbock, TX

Alok Vij, MD
Cleveland, OH

Melanie Wong, MD
Denver, CO

FIRST TIME ATTENDEES

Patrick Dahl
Fullerton, CA

Thomas Hocker, MD
Overland Park, KS

Kristina Holmkvist, MD
Fullerton, CA

Jeffrey Hsu, MD
Chicago, IL

Jeannette Jakus, MD, MBA
Riverdale, NY

Amer Kalaaji, MD
Rochester, MN

Julia Lehman, MD
Rochester, MN

Markham Luke, MD, PhD
Gaithersburg, MD

Jeffrey North, MD
Belmont, CA

Susan Taylor, MD
Wynnewood, PA

IN MEMORIAM

James Nordlund, MD
Harold Saferstein, MD



CME 13.50 *AMA PRA Category 1 Credits™*

Activity Purpose

As the advances in dermatology continue to progress, including therapeutic approaches and aesthetic procedures, the dermatologist must be able to stay connected to new treatments and procedures to maintain high quality of care. The goals of The Noah Worcester Annual Meeting, comprised of attendees from the US and Canada, are to optimize these learning goals by providing lectures, panels and discussion of topics as a broad overview of the advances in dermatology practice.

Target Audience

Dermatologists (general medical dermatologists, pediatric dermatologists, surgical dermatologists, and dermatopathologists).

Learning Objectives

At the conclusion of this event, participants should be able to:

- Identify barriers for patients and proper diagnosis treatment, and implement strategies to prescribing with value in the patient care setting.
- Employ practical skills to improve procedural techniques and patient's outcomes in cosmetic and surgical dermatology.
- Describe and utilize recently approved therapeutics for common dermatologic conditions.
- Improve adherence to evidence-based clinical guidelines for common dermatology conditions and medications in practice.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and the Noah Worcester Dermatological Society. NACE is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The National Association for Continuing Education designates this live activity for a maximum of 13.50 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Claim Your CME Credit and Certificate

1. After completing the course evaluation, login to your naceonline.com account. (Click Forgot Password button if you need to reset your password.)
2. Find the conference title on the "Events" tab of your Learner Dashboard and click on the "Start" or "Continue" button next to this course title.

3. Click the blue arrow to advance to the “Claim Your CME/CE Credit” page.
4. Review the instructions and click the blue arrow again to claim the credit amount commensurate with your participation.
5. Select the appropriate credit type(s) and number of credits from the dropdown menu on the left.
6. Your certificate will be available in the “Certifications” tab of the Learner Dashboard.

American with Disabilities

Any activity registrant who feels s/he may need accommodations based on the impact of a disability should contact the Noah Worcester Dermatological Society to discuss your specific needs.

Disclosure Policy

Accredited education provided by NACE must demonstrate balance, independence, objectivity, and scientific rigor. All individuals in a position to influence the content of NACE accredited education are required to disclose all financial relationships with ineligible companies within the previous 24-month period, regardless of relevance to the education. All relevant financial relationships and potential conflicts of interest have been mitigated prior to the activity.

NACE defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The content for this activity was developed independently of any ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or educational partner.

Summary of Individual Disclosures

Speaker and planner disclosures not available at time of printing. Disclosures provided on-site.

NACE and the Noah Worcester Dermatological Society staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

All relevant financial relationships have been mitigated prior to the meeting.

Disclosure of Unlabeled/Investigational Uses of Products

The content of the presentations may include discussion of unlabeled/unapproved uses of product or devices. If a speaker will discuss unlabeled/unapproved use of product or devices, it will be disclosed in each presentation.

Disclosure of Commercial Support

No commercial support was received for this activity.

Wednesday, May 3

2:00 PM – 7:00 PM **Registration** Pre-function Area

2:30 PM – 4:00 PM **Board of Trustees Meeting** Barrique

Thursday, May 4

7:00 AM – 2:00 PM **Registration** Pre-function Area

7:00 AM – 8:00 AM **Member Breakfast** Solera Courtyard

Non-CME Product Theaters Amphora A

7:00 AM – 7:30 AM **Non-CME Product Theater***
Lawrence Green, MD
presented by Amgen
**This is a non-CME accredited session*

7:30 AM – 8:00 AM **Non-CME Product Theater**
Adbry - The first and only biologic developed to specifically target and neutralize IL-13*
Neal Bhatia, MD
presented by LEO Pharma
**This is a non-CME accredited session*

Scientific Sessions Amphora B

8:00 AM – 8:15 AM **President's Welcome/Housekeeping**
Evan Schlamm, MD

8:15 AM – 8:30 AM **The Deliberative Biopsy: Clinical-Pathologic Correlation Begins and Ends at the Bedside**
Robert Brodell, MD

8:30 AM – 9:15 AM **PANEL: Genomics**
Moderator: Alina Bridges, DO
CP-GEP Gene Expression Profiling: Can My Melanoma Patient Forgo Sentinel Lymph Node Biopsy?
Alexander Meves, MD
Update on Gene Expression Profiling in Pigmented Lesions
Brook Brouha, MD
GEP and Melanoma with Minimal Dermoscopic Features
Maral Skelsey, MD

9:15 AM – 9:30 AM **Scientific Discussion**

9:30 AM – 10:15 AM

PANEL: Skin Cancer Therapeutics

Moderator: Neal Bhatia, MD

The Appropriateness of Mohs Surgery for Superficial Basal Cell Carcinoma

Howard Steinman, MD

An Update on the Treatment of Superficial Basal Cell Carcinoma

Andrew Ondo, MD

Actinic Keratosis Treatments and Photodynamic Therapy Update

Neal Bhatia, MD

10:15 AM – 10:30 AM

Update on Bullous Pemphigoid

Michael Camilleri, MD

10:30 AM – 10:45 AM

Resident Lecture Presentation

Epidermal iron content couples to systemic iron homeostasis and host defense

Shadi Khalil, MD

10:45 AM – 11:00 AM

Scientific Discussion

Non-CME Product Theaters

Amphora A

11:00 AM – 11:30 AM

Non-CME Product Theater

Step into Possibility: Discover Olumiant: the first FDA-approved systemic treatment for adults with severe alopecia areata (AA)*

Natasha Mesinkovska, MD

presented by Lilly

**This is a non-CME accredited session*

11:30 AM – 12:00 PM

Non-CME Product Theater*

A Targeted Approach to the Treatment of Nonsegmental Vitiligo*

Miriam Bettencourt, MD

presented by InCyte

**This is a non-CME accredited session*

Scientific Sessions

Amphora B

12:15 PM – 12:30 PM

A Pilot and a Dermatologist Walk into a Bar... (Applying Aviation Safety Concepts to Dermatology)

Peter Friedman, MD

12:30 PM – 12:45 PM

Rethinking the Way We Think: Avoiding Cognitive Bias in Dermatology and Dermatopathology

Julia Lehman, MD

12:45 PM – 1:00 PM

**Nutraceuticals and Skin Health:
To Supplement or Not?**

Radha Mikkilineni, MD

1:00 PM – 1:15 PM

**Pithy Pearl: Avoiding Hair Pitfalls in Skin
of Color Patients**

Susan Taylor, MD

1:15 PM – 1:30 PM

Data > Dogma

Thomas Hocker, MD

1:30 PM – 1:45 PM

**Emergency “Tele-Curbside” Encounters With an
Emphasis on Underserved-access and Medico-legal
Realities**

Louis Kuchnir, MD

1:45 PM – 2:00 PM

Scientific Discussion

---- Afternoon Break ----

4:00 PM – 4:50 PM

PINOT AND PEARLS

Moderators: Antoanella Calame, MD & Evan Schlam, MD

Skin Cancer: A Few Things That Surprised Me

Carla Bauman, MD

One Spot Wonders

Robin Berger, MD

**Rapid Response of Recalcitrant Prurigo
Nodularis to Dupilumab**

Raj Madhok, MD

The Inherent Photoprotective Neck

Matthew Harris, MD

Advocacy- Moving Forward!

Sabra Sullivan, MD

4:50 PM – 5:00 PM

Scientific Discussion

5:00 PM – 5:45 PM

PANEL: Aesthetic Updates 2023

Moderator: Lawrence Green, MD

Energy-Based Devices in Acne Treatment: What’s New

Valerie Callender, MD

My Experience with CryoAesthetics

Jeffrey Hsu, MD

**Mastering Jawline Contour with Injectables
in Your Practice**

Heidi Prather, MD

5:45 PM – 6:00 PM

Scientific Discussion

Friday, May 5

7:00 AM – 2:00 PM

Registration

Pre-function Area

7:00 AM – 8:00 AM

Member Breakfast

Solera Courtyard

Scientific Sessions

8:00 AM – 8:15 AM

Housekeeping

Amphora B

8:15 AM - 8:30 AM

Alfred L. Weiner MD Lecture Introduction

Natasha Mesinkovska, MD

8:30 AM - 9:15 AM

Alfred L. Weiner MD Lecture

Physician Burn Out: Is Creativity the Answer?

Shadi Kourosh, MD

9:15 AM - 9:30 AM

Scientific Discussion

9:30 AM - 9:45 AM

Harold O. Perry, MD Lecture Introduction

Alina Bridges, DO

9:45 AM - 10:30 AM

Harold O. Perry, MD Lecture

Approach to Hair Transplant in Scarring Alopecia

Meena Singh MD

10:30 AM - 10:45 AM

Scientific Discussion

10:45 AM – 11:00 AM

**Technology to Make Your Life Easier, Your Day
Smoother and Help You Go Green**

Daniel Siegel, MD

11:00 AM – 11:15 AM

**New Developments in Diagnosing Psoriasis and
Eczema**

Jeffrey North, MD

11:15 AM – 11:30 AM

**Direct-to-Consumer DNA Testing: Implications
for the Dermatologist**

Kristina Holmkvist, MD

Non-CME Product Theaters

Amphora A

11:30 AM – 12:00 PM

Non-CME Product Theater

Advancing Therapeutic Conversations*

George Michael Lewitt, MD

presented by AbbVie

**This is a non-CME accredited session*

12:00 PM – 12:30 PM

Non-CME Product Theater*

Darrell Rigel, MD

presented by Castle Biosciences

**This is a non-CME accredited session*

Scientific Sessions

Amphora B

12:45 PM – 1:00 PM

Who's Your Doctor and What's Your Hobby

Charles Perniciaro, MD

1:00 PM – 1:15 PM

Nail Pathology: Pearls and Perils

Beth Ruben, MD

1:15 PM – 1:30 PM

Resident Lecture Presentation

Efficacy of Topical and Intralesional Sodium

Thiosulfate in Calcinosis Cutis

Catherine Bridges, MD

1:30 PM – 1:45 PM

Scientific Discussion

Saturday, May 6

7:00 AM – 1:00 PM

Registration

Pre-function Area

7:00 AM – 8:00 AM

Member Breakfast

Solera Courtyard

Scientific Sessions

Amphora B

8:00 AM - 8:45 AM

Alfred L. Weiner MD Lecture

Timeless Dermatology: Novel Evidence for Classic Treatments

Shadi Kourosh, MD

8:45 AM – 9:00 AM

Scientific Discussion

9:00 AM – 9:45 AM

Harold O. Perry, MD Lecture

Non Surgical Therapies for Alopecia

Meena Singh MD

9:45 AM – 10:00 AM

Scientific Discussion

10:00 AM – 10:15 AM

AAD Update

Kenneth Tomecki, MD

10:15 AM – 10:30 AM

Update on Filler Complications

Joel Cohen, MD

10:30 AM – 10:45 AM	Generic Drugs and Dermatology - Bioequivalence and Access Equity <i>Markham Luke, MD</i>	
11:00 AM – 11:15 AM	Break	
11:00 AM – 11:45 AM	Business Meeting	Amphora B
<hr/>		
	<u>Non-CME Product Theaters</u>	Amphora A
11:45 AM – 12:15 PM	Non-CME Product Theater Comparative Conversations - Examination of Head to Head and Switching Data With Tremfya(Guselkumab) for Adults with Moderate to Severe Plaque Psoriasis* <i>Alison Ehrlich, MD</i> <i>presented by Janssen</i> <i>*This is a non-CME accredited session</i>	
<hr/>		
	<u>Scientific Sessions</u>	Amphora B
12:15 PM – 12:30 PM	Business Identity Theft <i>Patrick Dahl, MD</i>	
12:30 PM – 12:45 PM	Lasers & EBDs to Treat Acne and Rosacea – 2023 Update <i>Michael Gold, MD</i>	
12:45PM – 1:00 PM	Scientific Discussion	

SCIENTIFIC PRESENTATION ABSTRACTS

Thursday, May 4

8:15 AM – 8:30 AM

The Deliberative Biopsy: Clinical-Pathologic Correlation Begins and Ends at the Bedside

Robert Brodell, MD

This presentation is dedicated to Dr Fox and my mentor in dermatopathology Daniel J Santa Cruz, MD who passed away on March 30, 2020.

The unenlightened clinician submits a skin specimen to the lab and expects an “answer.” The experienced dermatologist knows that clinical-pathologic correlation begins before the knife touches the skin by selecting the most appropriate: 1) anatomic location for the biopsy; 2) type of biopsy; 3) depth and breadth of the biopsy; and 4) appropriate medium for hematoxylin and eosin staining (formalin) or direct immunofluorescence (Michel’s Transport Medium or normal saline). In addition, demographic information, anatomic location, clinical context, and differential diagnosis are all critical components of a properly completed requisition form. It has been less often been taught that proper biopsy design and appropriate grossing of the tissue at the bedside are often critical elements in getting “the answer.” This presentation highlights several examples to demonstrate that optimal clinical-pathologic correlation begins and ends at the bedside sandwiching the dermatopathology reading. The clinician **MUST** consider the needs of the pathologist when tissue is presented to the lab.

This discussion will demonstrate the optimal way to biopsy and prepare the specimen at the bedside for Porokeratosis of Mibelli, conditions with tense blisters, vitiligo, and sampling two adjacent lesions in a punch or shave specimen. This allows the dermatopathologist the best opportunity to make the best diagnosis for each patient. You will be convinced that collaborative dermatopathologic care begins and ends at the bedside with deliberative clinical-pathologic correlation.

8:30 AM – 9:15 AM

PANEL: Genomics, Moderator: Alina Bridges, DO

CP-GEP Gene Expression Profiling: Can My Melanoma Patient Forgo Sentinel Lymph Node Biopsy?

Alexander Meves, MD

Update on Gene Expression Profiling in Pigmented Lesions

Brook Brouha, MD

Some dermatologists use gene expression profiling (GEP) to aid in clinical decision making. There are two clinical scenarios regarding pigmented lesions. In one scenario, a patient presents for evaluation of a pigmented lesion. If the lesion falls below the clinician’s biopsy threshold, but malignancy cannot be excluded with absolute certainty, the clinician has the option of applying a non-invasive sticker to the lesion. The genetic material captured by the sticker can be tested to provide additional information. In the second scenario, a biopsy-proven invasive melanoma can be genetically categorized as more or less likely to behave aggressively. Tissue slices cut from the original pathology block are tested without need for additional biopsy. Over the past three years there has been a significant uptick in the use of genetics in the pigmented lesion field. I will discuss my own clinical experience in the context of emerging data.

GEP and Melanoma with Minimal Dermoscopic Features

Maral Skelsey, MD

9:30 AM – 10:15 AM

PANEL: Skin Cancer Therapeutics, Moderator: Neal Bhatia, MD

The Appropriateness of Mohs Surgery for Superficial Basal Cell Carcinoma

Howard Steinman, MD

An Update on the Treatment of Superficial Basal Cell Carcinoma

Andrew Ondo, MD

Superficial basal cell carcinoma is a frequently encountered tumor in any general or surgical dermatology practice. There are numerous treatments but studies with 5-year follow-up are few. This talk will highlight recent advances in the treatment of superficial basal cell carcinoma including preliminary data from a 5-year retrospective study.

Actinic Keratosis Treatments and Photodynamic Therapy Update

Neal Bhatia, MD

10:15 AM – 10:30 AM

Update on Bullous Pemphigoid

Michael Camilleri, MD

Bullous pemphigoid (BP) can present as an atypical non bullous presentation and confirmatory immunopathological tests are needed to reach the correct diagnosis. BP have been increasingly recognized to be associated with check point inhibitor therapy in oncology and dipeptidylpeptidase inhibitor therapy for diabetes mellitus. Various prognostic groups that direct appropriate therapy have been increasingly recognized. A variety of treatment options are available for BP, including potent topical corticosteroids, doxycycline, immunosuppressive agents, intravenous immunoglobulin, dupilumab, omalizumab, rituximab and several agents undergoing clinical trial.

10:30 AM – 10:45 AM

Resident Lecture Presentation

Epidermal iron content couples to systemic iron homeostasis and host defense

Shadi Khalil, MD

12:15 PM – 12:30 PM

A Pilot and a Dermatologist Walk into a Bar... (Applying Aviation Safety Concepts to Dermatology)

Peter Friedman, MD

Given the very high risks associated with flying and operating an aircraft, pilot training places a big emphasis on safety protocols. Practicing medicine is a similarly high-risk endeavor, and many of the concepts and principles pilots are taught can be adapted to help improve medical outcomes. Specific examples of aviation procedures and their translation into the daily practice of dermatology will be examined, with special emphasis on safety protocols concerning the pilot/dermatologist.

12:30 PM – 12:45 PM

Rethinking the Way We Think: Avoiding Cognitive Bias in Dermatology and Dermatopathology

Julia Lehman, MD

Each day, the average person makes tens of thousands of decisions. When related to the practice of medicine, even relatively simple decisions have the potential to cause (or prevent) patient harm. The purpose of this case-based talk is to familiarize the audience with common forms of cognitive bias that can lead to faulty decision-making in clinical medicine. By identifying these widespread unconscious vulnerabilities in human ways of thinking, the audience will learn ways to ensure rational, unbiased decision-making in their medical practice.

12:45 PM – 1:00 PM

Nutraceuticals and Skin Health: To Supplement or Not?

Radha Mikkilineni, MD

In recent years, the association between healthy skin, hair, nails, and nutrition has gained much attention. While it is well known that a balanced diet is recommended for overall health, there has been increasing emphasis on food and vitamins, minerals, and phytochemical components of food to enhance, prevent or improve skin health. These are collectively known as “nutraceuticals” or “dietary supplements” that are a subset of food taken orally. Broadly, there is an increasing acceptance among people of the idea that ‘what goes inside is seen outside. A number of factors contribute to this growing focus on nutrition, wellness, and a holistic and preventative approach to healthcare, including patient’s desire for autonomy in self-care and personal control of their health outcomes and decision-making process. Moreover, there is a desire to treat or manage health conditions and promote beauty with less toxic or pharmaceutical-grade medicines to avoid side effects. Unfortunately, the level of evidence for the use of supplements for the management of skin disease or improvement of skin health is either preliminary or equivocal in many cases, as large-scale studies are not required by the FDA and are challenging to conduct due to time expense and a lack of uniformity among supplement components. This talk will focus on when supplementation either through dietary changes or with the addition of vitamins, minerals and botanical remedies or a combination of both, may make sense.

1:00 PM – 1:15 PM

Pithy Pearls: Avoiding Hair Pitfalls in Skin of Color Patients

Susan Taylor, MD

1. Effective hair examination techniques
2. Tips for diagnosing frontal fibrosing alopecia
3. Dutasteride therapy for treatment of frontal fibrosing alopecia
4. Diagnosing traction alopecia
5. Treatment for central centrifugal cicatricial alopecia
6. Tips of treating seborrheic dermatitis

1:15 PM – 1:30 PM

Data > Dogma

Thomas Hocker, MD

Dermatologic surgery recommendations regarding “best surgical practices” are often poorly-supported by evidence. One topic within Dermatologic Surgery that warrants further investigation is the perioperative management of oral blood thinner medications, especially the newer, oral NOAC/DOAC blood thinners. In this lecture, we will re-visit and critically re-assess the primary data that guides our current recommendations regarding the management of these perioperative blood thinner medications.

1:30 PM – 1:45 PM

Emergency “Tele-Curbside” Encounters With an Emphasis on Underserved-access and Medico-legal Realities

Louis Kuchnir, MD

Dermatologists can choose to be available, affable, and helpful to our colleagues in emergency medicine. Alternatively, we can be perceived as riskaverse, avoidant and unhelpful. Our reputation and our job satisfaction may turn on our willingness to handle curbsides-by-text. I'll describe my experience with eight small hospitals over twenty years and shall make a persuasive case for opting-in!

4:00 PM – 4:50 PM

PINOT AND PEARLS, Moderators: Antoanella Calame, MD & Evan Schlam, MD

Skin Cancer: A Few Things That Surprised Me

Carla Bauman, MD

Will discuss a few cases that surprised me with review of the literature and connection to how this literature reflects my practice.

One Spot Wonders

Robin Berger, MD

Patients often are required to wait longer for an appointment than they feel comfortable with, and worry ensues. Waiting times for new and even older patients can exceed 2 months. Many of these lesions require only reassurance or a quick biopsy. We have developed a speed clinic for addressing isolated lesions of concern in a timely fashion. This Pithy Pearl will show our simple tips for setting up and running this clinic for a positive doctor and patient experience.

Rapid Response of Recalcitrant Prurigo Nodularis to Dupilumab

Raj Madhok

Introduction: Prurigo nodularis (PN) is a chronic, pruritic papular eruption of unclear etiology. Its persistence and associated chronic, severe pruritus make it difficult to treat and results in decreased quality of life. Dupilumab, an interleukin (IL) 4 receptor a inhibitor, approved for treating atopic dermatitis may result in rapid relief in this difficult to manage disease as demonstrated in this case.

Case Presentation: A 69-year old white female had a 13-year history of intractable pruritus and papules unresponsive to multiple therapeutic modalities. On exam she had multiple excoriated 3-10 mm inflamed papules with excoriations and crusts of the trunk, extremities, and scalp. There were multiple scars from chronic scratching. The diagnosis of prurigo nodularis was confirmed on multiple biopsies, including negative direct immunofluorescence, and normal lab work including anti-endomysial anti-

bodies, BP 180 and BP 230. Patch testing could not be performed due to diffuse skin involvement. Treatment with methotrexate, hydroxyzine, doxepin, levocetirizine, mycophenolic acid, azathioprine, topical steroids, N-acetyl cysteine, aprepitant, and oral antibiotics were ineffective. Narrow band UVB therapy, prednisone, and hospitalization for wet dressing therapy resulted in brief, mild improvement. She had chronic insomnia due to pruritus and episodes of secondary skin infections due to excoriations. Within 2 weeks of subcutaneous injection of dupilumab (600mg) followed by 300mg every 2 weeks she had dramatic reduction in pruritus and papules which continued to improve with ongoing treatment. Sleep improved and her quality of life was vastly improved with only occasional need for high potency topical steroids for spot treatment of new papules. Her only side effect was mild conjunctivitis commonly associated with this drug. She currently continues therapy.

Discussion: PN is typically a difficult condition to treat due to its unclear etiology and intensity of pruritus with associated excoriations, infections, and scarring. Recent reports of improvement with dupilumab offer a new, novel approach by blocking IL-4 and IL-13 which play a role in chronic itch. The mechanism of how it can reduce papules is unclear. Dupilumab has recently been approved by the FDA for use in prurigo nodularis.

The Inherent Photoprotective Neck

Matthew Harris

Over many years of clinical observation I have noted severe actinic damage on the posterior neck of patients, and in particular male patients, and yet anecdotally recall overall less skin cancers there than would be expected as compared to what I see on the face, lateral neck, etc.

I am going to review the pathology of multiple providers over the last 5 years and determine how many skin cancers were seen on the posterior neck (especially of males) compared to on other areas of intense sun damage.

If there is markedly less skin cancers on the posterior neck despite such intense actinic damage, I hypothesize there is some inherent biologic protection occurring and will discuss anything found in the literature that might help account for that. I also would propose this should be looked into at a deeper level to see if we can help utilize this protection for other areas of our skin.

Advocacy- Moving Forward!

Sabra Sullivan, MD

Pearls of wisdom learned over a professional lifetime to help you succeed in advocacy. Help move dermatology forward, not backwards!

5:00 PM – 5:45 PM

PANEL: Aesthetic Updates 2023, Moderator: Lawrence Green, MD

Energy-Based Devices in Acne Treatment: What's New

Valerie Callender, MD

Traditionally, the basis for the treatment of acne vulgaris is with topical and systemic therapies. However, there are many challenges and side effects associated with these medications, and patient compliance is a constant issue that impacts the therapeutic outcome in acne management. My presentation will review the published studies on energy-based devices for the treatment of acne and discuss treatment protocols for these devices.

My Experience with CryoAesthetics

Jeffrey Hsu, MD

Mastering Jawline Contour with Injectables in Your Practice

Heidi Prather, MD

Dermatologists should be comfortable in the art and techniques for aesthetic augmentation and safety. This presentation outlines the cosmetic evaluation and consult process for jawline contour and in depth clinical evidence based techniques for creating the ideal jawline contour and a review of anatomic safety

Friday, May 5

8:30 AM - 9:15 AM

Alfred L. Weiner MD Lecture

Physician Burn Out: Is Creativity the Answer?

Shadi Kourosh, MD

9:45 AM - 10:30 AM

Harold O. Perry, MD Lecture

Approach to Hair Transplant in Scarring Alopecia

Meena Singh MD

10:45 AM – 11:00 AM

Technology to Make Your Life Easier, Your Day Smoother and Help You Go Green

Daniel Siegel, MD

Technology in the form of apps and hardware can make your practice more efficient and help your patients. A variety of technology tips and pearls to help you in your professional life will be shared with the audience along with a complete handout of all materials presented.

11:00 AM – 11:15 AM

New Developments in Diagnosing Psoriasis and Eczema

Jeffrey North, MD

11:15 AM – 11:30 AM

Direct-to-Consumer DNA Testing: Implications for the Dermatologist

Kristina Holmkvist, MD

The cost and time required to analyze DNA has decreased dramatically over the past few decades. Consumers are now able to access their own genetic information without the involvement of a healthcare professional. What motivates people to pursue testing? What types of information are they finding? What are they doing with the data? What questions might they bring to a physician, especially those related to our specialty? What are the ethical and privacy issues? This presentation will take the participant on a brief tour of what is referred to as direct-to-consumer DNA testing.

12:45 PM – 1:00 PM

Who's Your Doctor and What's Your Hobby

Charles Perniciaro, MD

Clinical and histopathologic findings from two extraordinary patients are presented. One patient sought enhancement of his buttocks with filler substances. The second patient was an avid competitive swimmer.

1:00 PM – 1:15 PM

Nail Pathology: Pearls and Perils

Beth Ruben, MD

In this session, we will explore best practices to get the most out of specimens from the nail unit, select disease entities and diagnostic pitfalls.

1:15 PM – 1:30 PM

Resident Lecture Presentation

Efficacy of Topical and Intralesional Sodium Thiosulfate in Calcinosis Cutis

Catherine Bridges, MD

Calcinosis cutis has many etiologies and can be symptomatically or cosmetically bothersome to patients. Intralesional and topical sodium thiosulfate can provide improvement, and even resolution, of calcinosis cutis. Herein, the ideal concentration, technique, and “clinical pearls” of topical and intralesional sodium thiosulfate will be reviewed.

Saturday, May 6

8:00 AM - 8:45 AM

Alfred L. Weiner MD Lecture

Timeless Dermatology: Novel Evidence for Classic Treatments

Shadi Kourosh, MD

9:00 AM – 9:45 AM

Harold O. Perry, MD Lecture

Non Surgical Therapies for Alopecia

Meena Singh MD

10:00 AM – 10:15 AM

AAD Update

Kenneth Tomecki, MD

10:15 AM – 10:30 AM

Update on Filler Complications

Joel Cohen, MD

This lecture will review the spectrum of filler complications, including: superficial injection, sensitivity, infection, bruising and necrosis. We will have a focus on facial anatomy, as well as understanding, avoiding and managing these complications. Techniques and supplies to keep on hand will be discussed as well.

10:30 AM – 10:45 AM

Generic Drugs and Dermatology - Bioequivalence and Access Equity

Markham Luke, MD

Generic drugs are copies of brand-name drugs and are approved for marketing by the FDA via Abbreviated New Drug Applications (ANDAs).

Over 90% of U.S. prescriptions are for generic drugs, yet generic drugs constitute only about 18% of U.S. spending on prescription drugs. In 2021, \$373 billion was saved in the U.S. health care system (up from \$338 billion in 2020 because of generics and biosimilars. Medicare saved \$119 billion and commercial plans \$178 billion. At the consumer level, the average generic copay was \$6.16 vs. \$56.12 for brand-name drugs

(93% of generic fills are <\$20 vs. 59\$ for brand-name drugs. In 2021, 6.4 billion generic and biosimilar prescriptions were dispensed accounting for about 3% of U.S. health-care spending.

Complex drugs are defined as drugs that are more difficult to copy. They may have complex active pharmaceutical ingredients, complex route of delivery (e.g. via the skin instead of ingesting - resulting in greater difficulty in comparing drug levels at the site of action), complex formulation, or complexities due to product design (e.g. some drug-device combination products). Topical drugs for dermatology have had more dramatic price increases over the past decade than other types of drugs as per a 2016 report from the congressional GAO. The cost of these drugs have the potential for impacting access for our patients and may present challenges to healthcare equity due to cost prohibition.

Among the important research that FDA conducts is generic drug research on complex products, including topical drugs for dermatologic use. I will discuss some of the more recent research projects that we have been doing at FDA along with colleagues around the world. I will discuss some of the regulatory impact from such research, including new and more precise pathways to determination of bioequivalence.

12:15 PM – 12:30 PM

Business Identity Theft

Patrick Dahl, MD

Business identity theft occurs when criminals pose as an officer, employee or owner of a business to get cash, credit cards or loans in the name of the business. Thieves may open up lines of credit or take out loans in the name of the business. Thieves typically cash out quickly. The business theft often goes unnoticed until bills and collection notices arrive at the door of the victimized business. Common business identity theft schemes and how business identity theft can be prevented will be discussed.

12:30 PM – 12:45 PM

Lasers & EBDs to Treat Acne and Rosacea – 2023 Update

Michael Gold, MD

Acne and rosacea are some of the most common dermatologic disorders that dermatologists see on a regular basis in our offices. Dermatologists are fortunate to have some new topical and systemic therapies which work extremely well but some patients need more, and this is where EBD's may play a significant role. These devices for acne work mainly by targeting the P. acnes bacteria found in the pilosebaceous gland or in actual destruction of the sebaceous glands. Lasers & EBDs have also been shown to be beneficial for enhancing the effects for our rosacea patients as well. Clinical studies showing the efficacy of several devices will be reviewed, including the short-pulsed 1064 nm laser, the combination 589-1319 nm laser, the pulsed dye laser, the 1927 nm laser, and the intense pulsed light sources. Clinical studies showing the efficacy and safety of these devices will be shown. This presentation will show how these devices can be incorporated into one's clinical practice in a most successful manner.

NOAH WORCESTER DERMATOLOGICAL SOCIETY
ENDOWMENT FUND DONORS

Over \$500.00 lifetime contributions, listed in amount order.

GOLD CIRCLE

Murad Alam
Hiram Sturm*
Andrew Ondo and Karen Price
David and Nina Harvey
Peter and Karen Muelleman

SILVER CIRCLE

Jennifer Vesper and Thomas Andrews
Z. Charles Fixler

BRONZE CIRCLE

Michael and Amy O'Donoghue
Antoanella and Bart Calame
Lawrence and Allison Green
Eliabeth Abel*
Joel and Nancy Schlessinger
Elaine Young
George Lewitt

DONORS

Ronald and Ulla Barr
Daniel Siegel and Susan Byrde Siegel
James and Virginia Ertle
Neal and Sangita Bhatia
Mark and Maryann Zalla
James and Marna Zalla
Jeffrey and Pam Altman
Eileen Dyer
Kris and Cheri Howard
David and Teresa Shupp
Neil Sadick
Carla Bauman and Lucas Schenck
Gabriel and Mary Sciallis
Tamara and Ricco Scalise
Stuart Shanler
Raymond and Gina Welch

DONORS CONTINUED

Margaret Fitch and Ken Christensen
Charles and Gail Zugerman
Charles and Gail Perniciaro
Jason and Christin Smith
Thomas and Karla Davis
Alison Ehrlich and Robert Morse
Melanie Palm
Michael Tharp
Seemal and Nimisha Desai
Kathleen Hectorne
Selma and Jerome Targovnik
Peter and Eszter Friedman
Glenn and Sandy Dobecki
Robert and Linda Brodell
Gary and Claudette Cole
Henry and Kathie Roenigk, Jr.
Eleanor Weinstein

*Deceased

NOTES

NOTES

NOTES

SAVE THE DATES



NOAH 65TH ANNUAL MEETING

Wild Dunes, Isle of Palms, Charleston, SC
Tuesday, April 30 - Saturday, May 4, 2024

Registration opens November 2023



NOAH AAD RECEPTION

San Diego, CA
Friday, March 8, 2024

Registration opens November 2023